Sensitive diagnostic tools and targeted drug administration strategies are needed to eliminate schistosomiasis

Abena S. Amoah, PhD[1,2,3], Pytsje T. Hoekstra, MSc[1]*, Miriam Casacuberta-Partal, MSc[1], Luc E. Coffeng, PhD[4], Paul L.A.M. Corstjens, PhD[5], Beatrice Greco, PhD[6], Lisette van Lieshout, PhD[1], Mark D. Lim, PhD[7,8], Christine F. Markwalter, PhD[9,10], Maurice R. Odiere, PhD[11], Jutta Reinhard-Rupp, PhD[6], Meta Roestenberg, PhD[1,12], Prof Russell Stothard, PhD[13], Prof Louis-Albert Tchuem Tchuenté, PhD[14,15], Prof Sake J. de Vlas, PhD[4], Govert J. van Dam, PhD[1]

1. Department of Parasitology, Leiden University Medical Center, Leiden, The Netherlands.
2. Current affiliation: Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, Keppel Street, London, United Kingdom.
3. Current affiliation: Malawi Epidemiology and Intervention Research Unit, Chilumba, Karonga District, Malawi.
4. Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
5. Department of Cell and Chemical Biology, Leiden University Medical Center, Leiden, The Netherlands.
6. Global Health Institute of Merck (KGaA), Eysins, Switzerland.
7. Global Health Division, The Bill & Melinda Gates Foundation, Seattle, United States of America.
8. Current affiliation: Global Public Health Programs, American Society for Microbiology, Washington DC, United States of America.
9. Department of Chemistry, Vanderbilt University, Nashville, TN 37235, United States of America.
10. Current affiliation: Duke Global Health Institute, Duke University, Durham, NC 27710, United States of America.
11. Neglected Tropical Diseases Unit, Centre for Global Health Research, Kenya Medical Research Institute, Kisumu, Kenya.
12. Department of Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands.
13. Liverpool School of Tropical Medicine, Liverpool, United Kingdom.
14. Laboratory of Parasitology and Ecology, University of Yaoundé I, Yaoundé, Cameroon.
15. Centre for Schistosomiasis and Parasitology, Yaoundé, Cameroon.

*Corresponding author

Pytsje T. Hoekstra, Department of Parasitology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands.

Based on the Leiden Workshop on ‘Advancing CAA testing in low endemic settings of schistosomiasis’, September 2017

Abstract

Although preventive chemotherapy has been instrumental in reducing schistosomiasis worldwide, serious challenges remain. These include the omission of certain groups from mass drug administration campaigns, the existence of persistent disease hotspots as well as the risk of recrudescent infections. Central to these challenges is the fact that the currently prescribed diagnostic tools to establish the burden of infection lack sensitivity, especially in low endemic settings, resulting in an underestimation of the true prevalence of active *Schistosoma* infections. This necessitates a re-evaluation and possible adaptation of current WHO-recommended control strategies. Recently, more targeted interventions and novel approaches have been employed, such as establishing infection burden by precision mapping to provide high resolution spatial information that delineates significant variations in schistosomiasis prevalence within a defined geographical area. Such information is instrumental in guiding targeted intervention campaigns. However, the need for highly accurate diagnostic tools in such strategies remains a crucial factor that is often neglected. The availability of highly sensitive diagnostic tests also opens up the possibility of applying sample pooling strategies, to reduce control programme costs. To achieve interruption of transmission and eventually elimination of schistosomiasis, better local targeting of preventive chemotherapy in combination with utilising more sensitive diagnostic tools is vital.

Key-points

* Preventive chemotherapy has been key in reducing the burden of schistosomiasis but serious challenges remain

* Current diagnostic tools to detect *Schistosoma* infections as part of control programmes lack sensitivity

* Re-evaluation and adaption of current WHO-recommended schistosomiasis control strategies is urgently needed

* The use of highly sensitive diagnostic tools is key in breaking the transmission cycle and moving towards sustained elimination of schistosomiasis

Introduction

Despite years of sustained control efforts, the global burden of schistosomiasis remains high with an estimated 221 million people worldwide requiring preventive chemotherapy of which 90% resides in sub-Saharan Africa (1). This immense burden is exacerbated by the fact that schistosomiasis is strongly linked to poverty, limited access to potable water, and lack of adequate sanitation (2). Since 2001, the World Health Organisation (WHO) has strongly advocated for schistosomiasis morbidity control through preventive chemotherapy (World Health Assembly resolution 54·19 (3)) with a more recent expanded goal of elimination of schistosomiasis as a public health problem (World Health Assembly resolution 65·21 (4)).

While there have been successes in reducing the intensity of infections and associated morbidity through sustained mass drug administration (MDA) campaigns, schistosomiasis remains highly prevalent (5). In regions that have successfully reduced the intensity of infection to lower thresholds, the currently prescribed diagnostic tools are no longer reliable for control programmes treating these populations. Especially in areas with a low infection intensity these methods lack sensitivity and are therefore not able to accurately detect such low intensity infections and thereby underestimate the prevalence of active *Schistosoma* infections (6, 7). To break the cycle of transmission and shift towards sustained elimination of schistosomiasis, changes to the current global schistosomiasis control strategies are urgently needed (8, 9). The availability of more sensitive diagnostic tools presents opportunities to revisit these strategies in regions where a break in transmission may be feasible.

Strategic changes to advance the global control of schistosomiasis were discussed at an international workshop hosted by Leiden University Medical Center in the Netherlands in September 2017. The workshop brought together representatives from national control programmes, industry, donors and academia (research scientists, clinicians, and mathematical modellers) to develop a vision for sustained local interruption of transmission and the eventual successful elimination of schistosomiasis.

Challenges related to the current approach

The WHO's current strategy for controlling schistosomiasis focuses on reducing disease morbidity and transmission through periodic, targeted MDA with praziquantel (40 mg/kg body weight) administered to at-risk populations (10). As part of this strategy, the mean schistosomiasis prevalence is determined in an 'implementation unit (IU)'; a geographical area where an MDA programme is being rolled-out. This IU can be a whole district or a sub-district (Figure 1A), for example an administrative, health or education district and it varies in size from country to country (11).

Usually, in 5-10 sentinel sites within such an IU a parasitological survey is performed to determine the overall prevalence in the entire IU (Figure 1B) (9, 12). The sentinel site can be a school with 50 children per school being surveyed. Based on the mean prevalence determined by the survey, the risk of schistosomiasis is categorised as low (<10%), moderate (≥10% to <50%) or high (≥ 50%) for the whole IU (Figure 1C); a classification that defines the intervention strategy applied within this geographical area (13). Even though at sub-district level the burden of infection can be determined in more detail, this strategy does not sufficiently capture the focality of schistosomiasis, resulting in areas receiving over- or more importantly under-treatment (12).

Although initial implementation of the WHO MDA strategy has been successful in reducing morbidity (14-16) there are several opportunities for optimisation. MDA strategies traditionally target school-age children, a group within which the prevalence of schistosomiasis is often higher compared to other groups and which can be conveniently reached by programmes at one location (a school). However, this strategy fails to cover other groups that are at high risk of schistosome infection, for example preschool-age children and adults exposed to infested water through their occupations (e.g. fishermen, farmers, women doing laundry and irrigation workers) (17, 18). As such, these groups remain potential active reservoirs for continued transmission in a community. Preschool-age children are excluded due to safety concerns and poor adherence to praziquantel, although this concern is likely to be addressed with the development of a paediatric formulation for praziquantel (19). Likewise, WHO guidelines recommend the inclusion of pregnant and lactating women in MDA campaigns, but these groups often remain excluded also due to safety concerns despite the growing body of evidence demonstrating efficacy and safety of praziquantel for their treatment (20, 21). Exclusion of certain groups becomes a critical issue if the goal is community-wide control and elimination of schistosomiasis.

The commitment of Merck to support the WHO through the donation of praziquantel for preventive chemotherapy in school-aged children in Sub-Saharan Africa (22) has been pivotal to schistosomiasis control efforts. However, with the scale-up of MDA programmes, many African countries have been faced with the challenge of bridging the gap between the demand for praziquantel and what is available via the donation programme (23). Moreover, the currently recommended MDA dosage for praziquantel may be leading to suboptimal cure rates and prolonged low intensity infections within some communities. These consequences will be even more substantial and pronounced when percentages of population coverage of MDA will be reduced, leaving larger numbers of infected people untreated.

Additionally, in certain areas control of schistosomiasis is hampered by the existence of 'persistent hotspots'; geographical regions where MDA programmes have been in operation for several years, yet remain unable to achieve the forecasted declines in prevalence or intensity of schistosomiasis (24-27). Persistent hotspots have been identified across Africa including Kenya (28), Mali (29, 30), Sudan (31) and Tanzania (24, 32). These hotspots likely require approaches that combine MDA with multi-sectoral efforts such as health education, improvements to sanitation and potable water supply, environmental and vector control as well as future use of vaccines (33-37).

Another challenge in the control of schistosomiasis exists in parts of Asia where the prevalent schistosome species (*S. japonicum, S. mekongi and S. malayensis*) are known to be zoonotic and have several animal definitive hosts as a reservoir of infection (38). Also in African schistosomiasis, animal reservoirs have been described (39, 40). In such areas, the control and elimination of schistosomiasis is even more problematic since the management of animal reservoirs is imperative (38). In addition, molecular studies have also found evidence of genetic interactions between human and animal schistosomes within the African continent and the emergence of hybrid species indicative of some zoonotic spill-over (41, 42).

Classic diagnosis of schistosomiasis as part of control programmes is often still based on parasitological assessment of urine or stool, depending on the schistosome species endemic in the area. These diagnostic methods are known to lack sensitivity in detecting infections of low intensity, resulting in an underestimation of the burden of infection (7). Identifying areas with low infection intensities using accurate diagnostic tools combined with cost-effective strategies for implementation is essential for achieving elimination of schistosomiasis. This is also important for dealing with 'subtle morbidities' that could have long-term impact on the quality of life of individuals including effects on cognitive development (43). Control programmes struggle with how to tackle low prevalence settings where the factors sustaining transmission at lower levels are poorly understood and interruption of transmission has not yet been achieved (9, 33, 34). In addition, low endemic areas likely require continuous surveillance with highly sensitive diagnostic tools, as the risk of prematurely stopping MDA might very well result in infection levels returning to pre-MDA levels shortly after cessation of MDA (recrudescent infections) (37, 44). As for persistent hotspots, an integrated control approach is likely required to achieve these epidemiological targets.

Importance of precision mapping and more targeted interventions

Locating exactly where active transmission occurs and which individuals within a community still harbour living worm pairs, is particularly relevant as schistosomiasis is heterogeneously distributed, meaning that an endemic region can be considered as a collection of (micro)foci (45). There is a lack of clear guidelines that account for the potential effects of this natural heterogeneity, or focality, on programme design. Recent studies by the Schistosomiasis Consortium for Operational Research and Evaluation (SCORE) have shown a large variability in MDA efficacy at the community level (24, 28). Therefore, existing control guidelines need to be adapted with greater focus on geographical areas of low endemicity that are likely to achieve transmission interruption. In these areas, sampling grids can be narrowed by increasing the number of sites being sampled; a concept that has been termed 'precision mapping' (12). In order to demonstrate the precision mapping approach in Cameroon, Tchuem Tchuenté *et al* exhaustively sampled all schools in two schistosomiasis-endemic districts representing geographical areas characterised as being low and high with respect to schistosomiasis transmission (12). This approach produced high-resolution mapping information that showed significant variations in schistosomiasis prevalence between districts and sub-districts (called implementation units, IU), which would not have been detected with conventional mapping approaches that are part of the current global control strategies. Analysis of data from precision mapping can be used to guide targeted and intensified interventions in high-risk areas, providing a cost-efficient and judicious use of donated praziquantel. Furthermore, this approach presents an opportunity to zoom in on an IU to identify areas of significant transmission and the

advantage to specifically target the identification of individuals living in a low-endemic community who harbour significant intensities of living adult worms (the so called 'super-spreaders' (46)).

Importance of highly sensitive diagnostics

The success of any strategy to tackle schistosomiasis hinges on the ability to obtain an accurate picture of the burden of infection in a given community, as 'improvement can only come from accurate measurement' (Lord Kelvin, 1883) (47). The necessity of accurate diagnostic tools with high sensitivity in these strategies is often neglected. To achieve the goal of elimination of schistosomiasis, highly sensitive and specific diagnostic tools, that ideally are field-applicable, are needed to monitor the burden of infection.

Several diagnostic tools have demonstrated to be useful alternatives compared to conventional diagnostic methods currently used by national control programmes, such as the widely used field-applicable point-of-care circulating cathodic antigen (POC-CCA) test (48, 49). Even though this test has been recommended as a replacement for traditional microscopy (50), it is limited to the detection of intestinal schistosomiasis and still lacks sensitivity in detecting infections of low intensity (51, 52). A more promising alternative is the highly sensitive and specific laboratory-based up-converting phosphor lateral flow (UCP-LF) test that detects *Schistosoma* circulating anodic antigen (CAA) (53-56). It is a genus-specific test which detects all *Schistosoma* species in blood and urine samples, and may potentially be able to detect a single worm pair by increasing sample volume (56, 57). Furthermore, the UCP-LF CAA test is amenable to pooled sample testing strategies (58). Individuals whose pooled urine samples are found negative by the UCP-LF CAA test can be assumed to all be free of schistosome worms, or at least below a set threshold in worm load, while in CAA-positive urine pools, one or more individuals harbour a worm burden which might be relevant for further transmission. Individual urine samples can then be subsequently tested to identify infected individuals within a positive sample pool, in order to only treat infected individuals and thereby save drugs. Compared to more exhaustive sampling approaches, such pooling strategies can potentially reduce control programme costs (59). Although the UCP-LF CAA test is still lab-based, steps are underway to develop a more field-applicable version of this test (55, 58, 60). Clearly, a reliable and easy-to-use rapid diagnostic test is a prerequisite for the development of test-and-treat strategies, with or without pooled sampling, as well as to facilitate the clinical diagnosis of schistosomiasis at point-of-care settings and the targeted use of praziquantel.

Other more sensitive and specific diagnostics methods include polymerase chain reaction (PCR)-based methods for the detection of schistosome-specific DNA in clinical samples (urine, faeces or blood) (7, 61). One approach that has been designed for field use is loop-mediated isothermal amplification (LAMP), an advanced DNA-based detection method that amplifies DNA without a thermocycler and in some instances, can have higher sensitivity compared to conventional PCR (62-64). Another potentially field-applicable technique is isothermal recombinase polymerase amplification (RPA) for schistosome-specific DNA detection applicable to both *S. haematobium* (65) and *S. mansoni* (66).

Integrating sensitive diagnostics into an intensified focal test-and-treat strategy

In a theoretical schistosomiasis endemic area, comprised of one or more IUs, where the prevalence of infection has been determined to be low by standard parasitological methods (i.e. less than 10% overall prevalence and less than 1% prevalence of heavy infections), an intensified focal test-and-treat strategy, using highly accurate diagnostic tools, should at least be included to shift transmission dynamics within these geographical areas towards a break in transmission.

When applying the precision mapping approach in such an area, the burden of infection within an IU should be estimated from a larger number of sentinel sites, rather than a sampling from 5-10 sites as is conventionally recommended. This increased sampling from a larger number of sentinel sites would require pooling multiple samples in order to reduce the total number of tests needed as a cost-saving measure (58, 59). Given the focal nature of schistosomiasis, sampling designs should also consider proximity to water contact points where transmission is suspected.

In one scenario discussed at the workshop, an IU at sub-district level can be divided into separate 'transmission units' (TU, Figure 1D); a proposed geographical area limited to one or few transmission sites. So, instead of the current strategy in which 5-10 sentinel sites within an IU are being sampled, the whole IU is divided into smaller TUs. By integrating a pooling strategy using a highly sensitive diagnostic test, a whole TU will be

sampled and tested, leading to a quantitative evaluation of the overall infection burden within each TU. Mathematical modelling could provide valuable information on the best pooling strategy, taking into consideration age-groups or risk groups, as well as expected infection levels based on pre-control endemicity and history of control, to determine optimal pool size (58, 59). Information from existing databases on correlation between different diagnostic tests could also be used to develop a predictive model to estimate for example CAA or DNA loads and linking these individual measurements to transmission potential within a given area. The outcome of testing pooled samples with a highly sensitive diagnostic test in combination with the predictions of the model(s) would then guide the prevalence thresholds that should be set to determine the appropriate control strategy that will be embarked on within each TU.



Figure 1. Schematic representation illustrating the current strategy of sampling within an intervention unit in comparison to a mapping approach at a smaller level based on a pooled sampling strategy. Currently, according to the WHO, areas are divided into implementation units (IU) (A) which can vary in size; for example a whole district (A-i) or a sub-district (A-ii). The burden of infection in each IU is determined and monitored by sampling from 5-10 sentinel sites (B) using conventional parasitological diagnostic tools. The burden of infection is then categorised as low, moderate or high for each IU (C). By further dividing sub-district IUs into smaller transmission units (TU) (D), and instead of sampling from 5-10 sentinel sites applying a pooling strategy to the whole TU, a bigger area will be sampled from. This results in more accurate data for mapping and quantifying the distribution of schistosomiasis as well as to identify communities at risk.

Table 1: Proposed treatment strategy based on infection burden

Infection burden established by sampling	Recommended treatment strategy*
I. High infection burden	Intense MDA (annual or biannual treatment of all high-risk groups as well as community-wide treatment)
II. Medium infection burden	Regular MDA (annual community-wide treatment)
III. Low infection burden (near elimination)	Intensified focal test-and-treat (multiple rounds per year) and frequent surveillance, using the most sensitive diagnostic tool available in combination with pooled sampling
IV. No infection (anymore)	No MDA, regular surveillance, using the most sensitive diagnostic tool available in combination with pooled sampling

** Combined with integrated intervention measures, see text*

From the strategy outlined above, we envisage four scenarios that may reflect the burden of infection from surveying each TU (shown in Table 1). The corresponding recommended strategy should then also be implemented at TU level. In TUs found to have a high infection burden, for instance potential 'hotspots' or 'persistent hotspots', intense MDA of yearly or twice-yearly treatment should be rolled out following existing control strategies. Additional samples should be taken not only from school-age children, but also from high-risk groups (such as fishermen, car-washers, women doing laundry, etc.) and testing stratified according to these groups. The strategy could be adapted to treatment for each positive group in addition to all school-age children; and the entire group could be monitored and followed up over a two-year period. For TUs where a medium infection burden is established, a regular MDA programme of yearly community-wide treatment should be implemented. In areas where the burden of infection is found to be low, an intensified test-and-treat strategy with multiple rounds of testing and treating per year should be implemented after identifying the high-risk groups within each community. In addition, the identification, treatment and monitoring of individuals who still harbour high worm infections also needs to be taken into account in this strategy. Furthermore, knowledge about local transmission sites with respect to aquatic biology and social behaviour patterns is indispensable in tackling and reducing exposure. Individual worm levels could also be included to guide local or regional interventions. In TUs found to be negative, no MDA would be carried out but groups should be followed-up and tested over a given period of time using a cost-efficient sample pooling strategy. It would be important to know if these areas have always been negative or are negative after prolonged control since the monitoring approach depends on the potential for transmission in the area (best reflected by the pre-control endemicity). Obviously, all strategies also need to include other integrated multisectoral approaches such as health education, snail control, and water, sanitation and hygiene (WASH) initiatives. Classic xenomonitoring augmented with DNA methods that can identify infected snail hosts is especially important to determine environmental risk accurately (67), as well as monitoring of schistosome infection in locations where zoonotic spill-over may occur. Further innovations such analysis of water for environmental DNA (eDNA) (68), signatures of schistosomes with taxon specific probes, could be very powerful to verify putative interruptions of transmission.

At the national level, a surveillance response mechanism would need to monitor these focal test-and-treat strategies. This includes modelling for prediction and guiding the intervention, monitoring of infection and mechanisms to evaluate interventions (69). Global positioning system (GPS) mapping could be used to determine precise locations of infected people of all ages and their households (70). However, privacy issues need to be taken into consideration. Innovations such as surveying snail environmental DNA (eDNA) in water bodies (68, 71) are additional tools that can be used to monitor transmission. Lessons can also be learnt from the Global Polio Eradication Initiative which uses environmental surveillance of poliovirus in sewage to monitor the virus (72).

After presumed interruption of transmission has been achieved, communities should still, ideally, be monitored longitudinally using highly sensitive and specific assays using the UCP-LF CAA test and eventually also serology. After a number of years with no new infections being detected, new-borns and young children would have to be followed to assess their exposure to schistosomes (44, 73), which could be done through for example targeted anti-schistosomal antibody testing (74, 75). In addition, the movement of individuals from regions that are still endemic for schistosomiasis into post-transmission areas would have to be monitored, and infected individuals promptly treated. The development of commercially available highly sensitive tests would be indispensable in targeting these groups in this post-transmission phase.

Given that current schistosomiasis control programmes in sub-Saharan Africa rely heavily on donated praziquantel for MDA campaigns, the proposed test-and-treat strategy will enhance cost-efficiency. The availability of a paediatric praziquantel formulation for young children will further support and strengthen a community-wide targeted treatment approach.

The successful implementation and efficient rollout of the proposed strategy would hinge on close cooperation between key international players (such as WHO) and stakeholders within endemic countries. Within these countries, engagement with national and local authorities would guarantee local ownership and responsibility for the strategy and its implementation. Targeted implementation at more local levels such as a TU could be more complex due to logistical challenges and the lack of adequate structures. Therefore, strengthening overall neglected tropical disease (NTD) coordination structures at national and sub-national levels, including the building of local capacity, would assure the proper execution of the proposed strategy, as well as effective long-term monitoring, evaluation and overall sustainability.

Additionally, it would be essential that endemic countries adopt and incorporate the strategy into the development of their NTD master plans. This would be achieved through local and international stakeholders working closely with endemic country NTD expert committees that are responsible for coordinating the direction of national NTD goals and policies (including for schistosomiasis) and ensuring that these are in line with regional and global targets. Combining all these efforts is essential for improved focal targeting of preventive chemotherapy in combination with more sensitive diagnostic tools in order to achieve interruption of transmission and the eventual elimination of schistosomiasis.

Conclusion

The persistent global burden of schistosomiasis despite continuous large-scale MDA, requires a rethinking and revision of both intervention strategies and the diagnostic tools that enable these strategies. Especially in areas of low infection intensity, non-invasive pooled sample testing with highly accurate diagnostic tools should be implemented by national control programmes in adapted control strategies that ensure cost-efficiency in monitoring and evaluation, as well as longer-term surveillance. We believe this will be the way to go to achieve interruption of transmission and eventually elimination of schistosomiasis.

Contributors

ASA, GJD and PTH led the writing of this Personal View. All authors made contributions to the writing and discussions on the scope of this Personal View, and critically reviewed revisions and approved the final paper.

Funding

Logistics for this workshop were provided by funding through the Bill and Melinda Gates Foundation.

Declaration of interest

LEC gratefully acknowledges funding of the NTD Modelling Consortium by the Bill and Melinda Gates Foundation (OPP1184344) and funding from the Dutch Research Council (NWO, grant 016.Veni.178.023). CFM received support from the National Science Foundation, Graduate Research Opportunities Worldwide Fellowship, outside the submitted work. Dr. Reinhard-Rupp was employed by Merck KGaA at the time this Personal View was written, which did not impact her contribution to the article. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The views, opinions, assumptions or any other information set out in this Personal View are solely those of the authors and should not be attributed to the funders or any person connected with the funders.

References

1. WHO. Schistosomiasis 2019 [Available from: https://www.who.int/en/news-room/fact-sheets/detail/schistosomiasis.
2. Grimes JE, Croll D, Harrison WE, Utzinger J, Freeman MC, Templeton MR. The relationship between water, sanitation and schistosomiasis: a systematic review and meta-analysis. PLoS Negl Trop Dis. 2014;8(12):e3296.
3. WHO. WHA54.19 Schistosomiasis and soil-transmitted helminth infections Geneva, Switzerland: WHO; 2001 [Available from: https://www.who.int/neglected_diseases/mediacentre/WHA_54.19_Eng.pdf?ua=1.
4. WHO. Resolution on schistosomiasis WHA65.21 Geneva, Switzerland: WHO; 2012 [Available from: https://www.who.int/neglected_diseases/Schistosomiasis_wha65/en/.
5. French MD, Evans D, Fleming FM, Secor WE, Biritwum NK, Brooker SJ, et al. Schistosomiasis in Africa: Improving strategies for long-term and sustainable morbidity control. PLoS Negl Trop Dis. 2018;12(6):e0006484.
6. Le L, Hsieh MH. Diagnosing Urogenital Schistosomiasis: Dealing with Diminishing Returns. Trends in parasitology. 2017;33(5):378-87.
7. Utzinger J, Becker SL, van Lieshout L, van Dam GJ, Knopp S. New diagnostic tools in schistosomiasis. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2015;21(6):529-42.
8. Lo NC, Addiss DG, Hotez PJ, King CH, Stothard JR, Evans DS, et al. A call to strengthen the global strategy against schistosomiasis and soil-transmitted helminthiasis: the time is now. The Lancet Infectious diseases. 2017;17(2):e64-e9.
9. Tchuem Tchuente LA, Rollinson D, Stothard JR, Molyneux D. Moving from control to elimination of schistosomiasis in sub-Saharan Africa: time to change and adapt strategies. Infectious diseases of poverty. 2017;6(1):42.
10. WHO. Schistosomiasis Geneva: World Health Organization; 2017 [Available from: http://www.who.int/mediacentre/factsheets/fs115/en/.
11. WHO. Report of an Informal Consultation on Schistosomiasis Control. Geneva, Switzerland: WHO; 2013.
12. Tchuem Tchuente LA, Stothard JR, Rollinson D, Reinhard-Rupp J. Precision mapping: An innovative tool and way forward to shrink the map, better target interventions, and accelerate toward the elimination of schistosomiasis. PLoS Negl Trop Dis. 2018;12(8):e0006563.
13. WHO. Schistosomiasis: Progress Report 2001 - 2011 and Strategic Plan 2012 - 2020 Geneva: World Health Organization; 2013.
14. Kabatereine NB, Brooker S, Koukounari A, Kazibwe F, Tukahebwa EM, Fleming FM, et al. Impact of a national helminth control programme on infection and morbidity in Ugandan schoolchildren. Bulletin of the World Health Organization. 2007;85(2):91-9.
15. Koukounari A, Gabrielli AF, Toure S, Bosque-Oliva E, Zhang Y, Sellin B, et al. Schistosoma haematobium infection and morbidity before and after large-scale administration of praziquantel in Burkina Faso. The Journal of infectious diseases. 2007;196(5):659-69.
16. Andrade G, Bertsch DJ, Gazzinelli A, King CH. Decline in infection-related morbidities following drug-mediated reductions in the intensity of *Schistosoma* infection: a systematic review and meta-analysis. PLoS Negl Trop Dis. 2017;11(2):e0005372.
17. Osakunor DNM, Woolhouse MEJ, Mutapi F. Paediatric schistosomiasis: What we know and what we need to know. PLoS Negl Trop Dis. 2018;12(2):e0006144.
18. WHO. Schistosomiasis: Key Facts Geneva: World Health Organization; 2018 [updated 20 February 2018. Available from: http://www.who.int/news-room/fact-sheets/detail/schistosomiasis.
19. Hussaarts L, van der Weijde K, Dome P, Kourany-Lefoll E, Reinhard-Rupp J, de Vrueh R. Product development programs for neglected tropical diseases: A crucial role for expert meetings. PLoS Negl Trop Dis. 2017;11(2):e0005183.

20. Olveda RM, Acosta LP, Tallo V, Baltazar PI, Lesiguez JL, Estanislao GG, et al. Efficacy and safety of praziquantel for the treatment of human schistosomiasis during pregnancy: a phase 2, randomised, double-blind, placebo-controlled trial. The Lancet Infectious diseases. 2016;16(2):199-208.
21. Friedman JF, Olveda RM, Mirochnick MH, Bustinduy AL, Elliott AM. Praziquantel for the treatment of schistosomiasis during human pregnancy. Bulletin of the World Health Organization. 2018;96(1):59-65.
22. Merck. Making Schistory. Darmstadt, Germany: Merck KGaA; 2020 [Available from: https://www.merckgroup.com/en/company/responsibility/our-strategy/global-health/schistosomiasis.html.
23. Wang X-Y, He J, Juma S, Kabole F, Guo J-G, Dai J-R, et al. Efficacy of China-made praziquantel for treatment of Schistosomiasis haematobium in Africa: A randomized controlled trial. PLoS neglected tropical diseases. 2019;13(4):e0007238-e.
24. Kittur N, Binder S, Campbell CH, King CH, Kinung'hi S, Olsen A, et al. Defining Persistent Hotspots: Areas That Fail to Decrease Meaningfully in Prevalence after Multiple Years of Mass Drug Administration with Praziquantel for Control of Schistosomiasis. The American journal of tropical medicine and hygiene. 2017;97(6):1810-7.
25. Al-Shehri H, Stanton MC, LaCourse JE, Atuhaire A, Arinaitwe M, Wamboko A, et al. An extensive burden of giardiasis associated with intestinal schistosomiasis and anaemia in school children on the shoreline of Lake Albert, Uganda. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2016;110(10):597-603.
26. Stothard JR, Kabatereine NB, Archer J, Al-Shehri H, Tchuem-Tchuenté LA, Gyapong M, et al. A centenary of Robert T. Leiper's lasting legacy on schistosomiasis and a COUNTDOWN on control of neglected tropical diseases. Parasitology. 2017;144(12):1602-12.
27. Kittur N, King CH, Campbell CH, Kinung'hi S, Mwinzi PNM, Karanja DMS, et al. Persistent Hot spots in Schistosomiasis Consortium for Operational Research and Evaluation Studies for Gaining and Sustaining Control of Schistosomiasis after Four Years of Mass Drug Administration of Praziquantel. The American journal of tropical medicine and hygiene. 2019.
28. Wiegand RE, Mwinzi PNM, Montgomery SP, Chan YL, Andiego K, Omedo M, et al. A Persistent Hotspot of Schistosoma mansoni Infection in a Five-Year Randomized Trial of Praziquantel Preventative Chemotherapy Strategies. The Journal of infectious diseases. 2017;216(11):1425-33.
29. Clements AC, Bosque-Oliva E, Sacko M, Landoure A, Dembele R, Traore M, et al. A comparative study of the spatial distribution of schistosomiasis in Mali in 1984-1989 and 2004-2006. PLoS Negl Trop Dis. 2009;3(5):e431.
30. Landoure A, Dembele R, Goita S, Kane M, Tuinsma M, Sacko M, et al. Significantly reduced intensity of infection but persistent prevalence of schistosomiasis in a highly endemic region in Mali after repeated treatment. PLoS Negl Trop Dis. 2012;6(7):e1774.
31. Ahmed AM, El Tash LA, Mohamed EY, Adam I. High levels of Schistosoma mansoni infections among schoolchildren in central Sudan one year after treatment with praziquantel. Journal of helminthology. 2012;86(2):228-32.
32. Poggensee G, Krantz I, Nordin P, Mtweve S, Ahlberg B, Mosha G, et al. A six-year follow-up of schoolchildren for urinary and intestinal schistosomiasis and soil-transmitted helminthiasis in Northern Tanzania. Acta tropica. 2005;93(2):131-40.
33. Ross AG, Chau TN, Inobaya MT, Olveda RM, Li Y, Harn DA. A new global strategy for the elimination of schistosomiasis. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2017;54:130-7.
34. Bergquist R, Zhou XN, Rollinson D, Reinhard-Rupp J, Klohe K. Elimination of schistosomiasis: the tools required. Infectious diseases of poverty. 2017;6(1):158.
35. Hotez PJ, Bottazzi ME, Bethony J, Diemert DD. Advancing the Development of a Human Schistosomiasis Vaccine. Trends in parasitology. 2019;35(2):104-8.

36. Fenwick A. Schistosomiasis research and control since the retirement of Sir Patrick Manson in 1914. Transactions of The Royal Society of Tropical Medicine and Hygiene. 2017;111(5):191-8.
37. Bergquist R, Yang GJ, Knopp S, Utzinger J, Tanner M. Surveillance and response: Tools and approaches for the elimination stage of neglected tropical diseases. Acta tropica. 2015;141(Pt B):229-34.
38. Gordon CA, Kurscheid J, Williams GM, Clements ACA, Li Y, Zhou XN, et al. Asian Schistosomiasis: Current Status and Prospects for Control Leading to Elimination. Trop Med Infect Dis. 2019;4(1).
39. Catalano S, Sene M, Diouf ND, Fall CB, Borlase A, Leger E, et al. Rodents as Natural Hosts of Zoonotic Schistosoma Species and Hybrids: An Epidemiological and Evolutionary Perspective From West Africa. The Journal of infectious diseases. 2018;218(3):429-33.
40. Duplantier JM, Sene M. Rodents as reservoir hosts in the transmission of Schistosoma mansoni in Richard-Toll, Senegal, West Africa. Journal of helminthology. 2000;74(2):129-35.
41. Webster BL, Alharbi MH, Kayuni S, Makaula P, Halstead F, Christiansen R, et al. Schistosome Interactions within the Schistosoma haematobium Group, Malawi. Emerging infectious diseases. 2019;25(6):1245-7.
42. Webster BL, Diaw OT, Seye MM, Webster JP, Rollinson D. Introgressive hybridization of Schistosoma haematobium group species in Senegal: species barrier break down between ruminant and human schistosomes. PLoS Negl Trop Dis. 2013;7(4):e2110.
43. Sircar AD, Mwinzi PNM, Onkanga IO, Wiegand RE, Montgomery SP, Secor WE. Schistosoma mansoni Mass Drug Administration Regimens and Their Effect on Morbidity among Schoolchildren over a 5-Year Period-Kenya, 2010-2015. The American journal of tropical medicine and hygiene. 2018;99(2):362-9.
44. Secor WE, Colley DG. When Should the Emphasis on Schistosomiasis Control Move to Elimination? Trop Med Infect Dis. 2018;3(3).
45. Gryseels B, Nkulikyinka L. The distribution of Schistosoma mansoni in the Rusizi plain (Burundi). Annals of tropical medicine and parasitology. 1988;82(6):581-90.
46. WHO. Elimination of schistosomiasis from low-transmission areas: Report of a WHO Informal Consultation. Geneva, Switzerland: WHO; 2009.
47. Thomson W. Popular Lectures and Addresses: Volume 1: Constitution of Matter. Cambridge: Cambridge University Press; 2011.
48. Colley DG, Binder S, Campbell C, King CH, Tchuem Tchuenté LA, N'Goran EK, et al. A five-country evaluation of a point-of-care circulating cathodic antigen urine assay for the prevalence of *Schistosoma mansoni*. The American journal of tropical medicine and hygiene. 2013;88(3):426-32.
49. Kittur N, Castleman JD, Campbell CH, Jr., King CH, Colley DG. Comparison of *Schistosoma mansoni* prevalence and intensity of infection, as determined by the circulating cathodic antigen urine assay or by the Kato-Katz fecal assay: a systematic review. The American journal of tropical medicine and hygiene. 2016;94(3):605-10.
50. Bärenbold O, Garba A, Colley DG, Fleming FM, Haggag AA, Ramzy RMR, et al. Translating preventive chemotherapy prevalence thresholds for *Schistosoma mansoni* from the Kato-Katz technique into the point-of-care circulating cathodic antigen diagnostic test. PLoS Negl Trop Dis. 2018;12(12):e0006941.
51. Sousa MS, van Dam GJ, Pinheiro MCC, de Dood CJ, Peralta JM, Peralta RHS, et al. Performance of an ultra-sensitive assay targeting the circulating anodic antigen (CAA) for detection of *Schistosoma mansoni* infection in a low endemic area in Brazil. Front Immunol. 2019;10(682).
52. Obeng BB, Aryeetey YA, de Dood CJ, Amoah AS, Larbi IA, Deelder AM, et al. Application of a circulating-cathodic-antigen (CCA) strip test and real-time PCR, in comparison with microscopy, for the detection of Schistosoma haematobium in urine samples from Ghana. Annals of tropical medicine and parasitology. 2008;102(7):625-33.

53. Corstjens PL, van Lieshout L, Zuiderwijk M, Kornelis D, Tanke HJ, Deelder AM, et al. Up-converting phosphor technology-based lateral flow assay for detection of Schistosoma circulating anodic antigen in serum. Journal of clinical microbiology. 2008;46(1):171-6.
54. Corstjens PL, De Dood CJ, Kornelis D, Fat EM, Wilson RA, Kariuki TM, et al. Tools for diagnosis, monitoring and screening of Schistosoma infections utilizing lateral-flow based assays and upconverting phosphor labels. Parasitology. 2014;141(14):1841-55.
55. Corstjens PL, Nyakundi RK, de Dood CJ, Kariuki TM, Ochola EA, Karanja DM, et al. Improved sensitivity of the urine CAA lateral-flow assay for diagnosing active Schistosoma infections by using larger sample volumes. Parasit Vectors. 2015;8:241.
56. Knopp S, Corstjens PL, Koukounari A, Cercamondi CI, Ame SM, Ali SM, et al. Sensitivity and Specificity of a Urine Circulating Anodic Antigen Test for the Diagnosis of Schistosoma haematobium in Low Endemic Settings. PLoS Negl Trop Dis. 2015;9(5):e0003752.
57. Wilson RA, van Dam GJ, Kariuki TM, Farah IO, Deelder AM, Coulson PS. The detection limits for estimates of infection intensity in schistosomiasis mansoni established by a study in non-human primates. International journal for parasitology. 2006;36(12):1241-4.
58. Corstjens P, Hoekstra PT, de Dood CJ, van Dam GJ. Utilizing the ultrasensitive Schistosoma up-converting phosphor lateral flow circulating anodic antigen (UCP-LF CAA) assay for sample pooling-strategies. Infectious diseases of poverty. 2017;6(1):155.
59. Lo NC, Coulibaly JT, Bendavid E, N'Goran EK, Utzinger J, Keiser J, et al. Evaluation of a Urine Pooling Strategy for the Rapid and Cost-Efficient Prevalence Classification of Schistosomiasis. PLoS Negl Trop Dis. 2016;10(8):e0004894.
60. Markwalter CF, Corstjens P, Mammoser CM, Camps G, van Dam GJ, Wright DW. Poly(amidoamine)-coated magnetic particles for enhanced detection of Schistosoma circulating anodic antigen in endemic urine samples. The Analyst. 2018;144(1):212-9.
61. Meurs L, Brienen E, Mbow M, Ochola EA, Mboup S, Karanja DM, et al. Is PCR the next reference standard for the diagnosis of *Schistosoma* in stool? A comparison with microscopy in Senegal and Kenya. PLoS Negl Trop Dis. 2015;9(7):e0003959.
62. Xu J, Rong R, Zhang HQ, Shi CJ, Zhu XQ, Xia CM. Sensitive and rapid detection of Schistosoma japonicum DNA by loop-mediated isothermal amplification (LAMP). International journal for parasitology. 2010;40(3):327-31.
63. Lodh N, Mikita K, Bosompem KM, Anyan WK, Quartey JK, Otchere J, et al. Point of care diagnosis of multiple schistosome parasites: Species-specific DNA detection in urine by loop-mediated isothermal amplification (LAMP). Acta tropica. 2017;173:125-9.
64. Gandasegui J, Fernandez-Soto P, Muro A, Simoes Barbosa C, Lopes de Melo F, Loyo R, et al. A field survey using LAMP assay for detection of Schistosoma mansoni in a low-transmission area of schistosomiasis in Umbuzeiro, Brazil: Assessment in human and snail samples. PLoS Negl Trop Dis. 2018;12(3):e0006314.
65. Rosser A, Rollinson D, Forrest M, Webster BL. Isothermal Recombinase Polymerase amplification (RPA) of Schistosoma haematobium DNA and oligochromatographic lateral flow detection. Parasit Vectors. 2015;8:446.
66. Poulton K, Webster B. Development of a lateral flow recombinase polymerase assay for the diagnosis of Schistosoma mansoni infections. Analytical biochemistry. 2018;546:65-71.
67. Schols R, Carolus H, Hammoud C, Mulero S, Mudavanhu A, Huyse T. A rapid diagnostic multiplex PCR approach for xenomonitoring of human and animal schistosomiasis in a 'One Health' context. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2019.
68. Sengupta ME, Hellstrom M, Kariuki HC, Olsen A, Thomsen PF, Mejer H, et al. Environmental DNA for improved detection and environmental surveillance of schistosomiasis. Proceedings of the National Academy of Sciences of the United States of America. 2019;116(18):8931-40.
69. Zhou XN, Bergquist R, Tanner M. Elimination of tropical disease through surveillance and response. Infectious diseases of poverty. 2013;2(1):1.

519 70. Angelo T, Buza J, Kinung'hi SM, Kariuki HC, Mwanga JR, Munisi DZ, et al. Geographical and
520 behavioral risks associated with Schistosoma haematobium infection in an area of complex
521 transmission. Parasit Vectors. 2018;11(1):481.
522 71. Campbell SJ, Stothard JR, O'Halloran F, Sankey D, Durant T, Ombede DE, et al. Urogenital
523 schistosomiasis and soil-transmitted helminthiasis (STH) in Cameroon: An epidemiological update at
524 Barombi Mbo and Barombi Kotto crater lakes assessing prospects for intensified control
525 interventions. Infectious diseases of poverty. 2017;6(1):49.
526 72. Asghar H, Diop OM, Weldegebriel G, Malik F, Shetty S, El Bassioni L, et al. Environmental
527 surveillance for polioviruses in the Global Polio Eradication Initiative. The Journal of infectious
528 diseases. 2014;210 Suppl 1:S294-303.
529 73. Colley DG, Andros TS, Campbell CH, Jr. Schistosomiasis is more prevalent than previously
530 thought: what does it mean for public health goals, policies, strategies, guidelines and intervention
531 programs? Infectious diseases of poverty. 2017;6(1):63.
532 74. Global Health Innovative Technology Fund. Novel diagnostics for schistosomiasis control:
533 development of defined antigens for detection of Schistosoma infection-specific antibodies in blood
534 and urine: Global Health Innovative Technology Fund; 2017 [Available from:
535 https://www.ghitfund.org/investment/portfoliodetail/detail/123.
536 75. de Dood CJ, Hoekstra PT, Mngara J, Kalluvya SE, van Dam GJ, Downs JA, et al. Refining
537 Diagnosis of Schistosoma haematobium Infections: Antigen and Antibody Detection in Urine.
538 Frontiers in immunology. 2018;9:2635.
539 76. Naus CWA, van Remoortere A, Ouma JH, Kimani G, Dunne DW, Kamerling JP, et al. Specific
540 Antibody Responses to Three Schistosome-Related Carbohydrate Structures in Recently Exposed
541 Immigrants and Established Residents in an Area of Schistosoma mansoni Endemicity. Infection and
542 Immunity. 2003;71(10):5676-81.